|
| | cGVHD | aGVHD |
|
| Number | = 125 | = 113 |
|
| Age | 30 (2–60) years | 35 (2–59) |
|
Type
Steroid refractory
Steroid naïve |
= 39
= 86 |
= 59
= 54 |
|
| Stage | Limited = 40
Extensive = 85 | I-II = 67
III-IV = 46 |
|
Previous immune suppression
MTX containing
Non-MRTX containing
None |
= 34
= 105
6 |
= 113
= 51
0 |
|
MTX
Dose
Number of doses |
7.5 (3–15) mg /m2/w
4 (3–50) |
7.5 (3–15) mg/m2/w
3 (2–60) |
|
Response
OR
CR
PR
NR |
97/125 (77.6%)
62/125 (49.6%)
35/125 (28%)
28/125 (22.4%) |
79/113 (69.9%)
67/113 (59.2%)
12/113 (10.6%)
34/113 (30%) |
|
| Response by stage | Limited 33/40 (82.5%)
Extensive 62/85 (72.9%) | I-II 50/58 (86%)
III-IV 11/20 (55%) |
|
Response by organ
Skin
Oral mucosa
GIT
Liver
Pulmonary |
60/78 (77%)
17/40 (42.5%)
4/8 (50%)
50/69 (72%)
2/2 (100%) |
72/89 (80.8%)
35/57 (61.4%)
11/23 (47.8%) |
|
Response by number of organs involved
Single organ
OR
CR
Multiorgan involvement
OR
CR |
61/73 (83.5%)
49/73 (67.1%)
32/41 (78%)
13/41 (31.7%) |
47/60 (78.3%)
47/60 (78.3%)
24/38 (63.1%)
19/38 (50%) |
|
Discontinue or reduce IS
Continue or increase other IS | 99/125 (79.2%)
26/125 (20.8%) | 67/113 (59.3)
46/113 (40.7%) |
|
Toxicity
Hematologic toxicity
Hepatic toxicity
Mucosal toxicity
Pulmonary toxicity |
Grade 3 or more = 22/125 (17.6%)
<Grade 2
<Grade 2
<Grade 2 |
Grade 3 or more = 47/113 (41.5%)
Grade 3 or more = 4/113 (3.5%) |
|
| Survival at least one year after GVHD | 115/125 (92%) | 84/113 (74.3%) |
|
Cause of death
Uncontrolled GVHD
Relapse
Infectious complications
Hemorrhage
Multiorgan failure |
—
5/125 (4%)
5/125 (4%)
—
— |
= 11/113
= 10/113
= 7/113
= 2/113
= 1/113 |
|
